Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or Plasmalyte

Transfusion

Volumn 50, Issue 10, 2010, Pages 2199-2209

  Slichter, Sherrill J ^a,b   Bolgiano, Doug ^a   Corson, Jill ^a   Jones, Mary Kay ^a   Christoffel, Todd ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; INDIUM 111; PLASMALYTE; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; PLASMA; THROMBOCYTE PRESERVATION; THROMBOCYTE RICH PLASMA;

BLOOD PLATELETS; BLOOD PRESERVATION; CELL SURVIVAL; HUMANS; PLATELET-RICH PLASMA; TIME FACTORS;

EID: 78649461283     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02669.x     Document Type: Article

References (42)

1. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology Am Soc Hematol Educ Program 2003:575-89.
2. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a noval psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
3. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000;78 Suppl 2:211-5.
4. Brecher ME, Means N, Jere CS, Heath DG, Rothenberg S, Stutzman LC. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. Transfusion 2001;41:477-82.
5. Ortolano GA, Freundlich LF, Holme S, Russell RL, Cortus MA, Wilkins K, Nomura H, Chong C, Carmen R, Capetandes A, Wenz B. Detection of bacteria in WBC-reduced PLT concentrates using percent oxygen as a marker for bacteria growth. Transfusion 2003;43:1276-85.
6. Brecher ME, Hogen JJ, Boothe G, Kerr A, McClannan L, Jacobs MR, Yomtovian R, Chongokolwatana V, Tegtmeier G, Henderson S, Pineda A, Halling V, Kemper M, Kuramato K, Holland PV, Longiaru M. Platelet bacterial contamination and the use of a chemiluminescence-linked universal bacterial ribosomal RNA gene probe. Transfusion 1994;34: 750-5.
7. Dumont LJ, AuBuchon JP, Whitley P, Herschel LH, Johnson A, McNeil D, Sawyer S, Roger JC. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002;42:847-54.
8. FDA. Center for Biologics Evaluation and Research. Minutes of the FDA Blood Products Advisory Committee Meeting of July 22, 2004. [cited 2010 Apr 12]. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/ transcripts/2004- 4057t1.htm
9. Kleinman S, Dumont LJ, Tomasulo P, Bianco C, Katz L, Benjamin RJ, Gajic O, Brecher ME. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion 2008;49: 903-12.
10. Vostal JG. Efficacy evaluation of current and future platelet transfusion products. J Trauma 2006;60(6 Suppl): S78-82.
11. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L, euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
12. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, David K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation. The SPRINT Trial. Blood 2004;104:1534-41.
13. Murphy S. Radiolabeling of PLTs to assess viability: a proposal for a standard. Transfusion 2004;44:131-3.
14. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985;66:1105-9.
15. FDA. Center for Biologics Evaluation and Research. FDA Blood Products Advisory Committee, March 13-14, 2003. [cited 2010 Apr 12]. Available from: URL: http:// www.fda.gov/ohrms/dockets/ac/03/transcripts/ 3940t1.htm and http://www.fda.gov/ohrms/dockets/ac/ 03/transcripts/3940t2.htm.
16. Murphy S. The case for a new approach for documenting platelet viability. Transfusion 2006;46 Suppl 3:49S-52S.
17. Taylor HL, Whitley P, Heaton A. A historical perspective on platelet radiolabeling techniques. Transfusion 2006;46 Suppl 3:53S-58S.
18. Dumont LJ. Analysis and reporting of platelet kinetic studies. Transfusion 2006;46 Suppl 3:67S-73S.
19. The Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Platelet radiolabeling procedure. Transfusion 2006;46 Suppl 3:59S-66S.
20. Adams GA, Swenson SD, Rock G. Survival and recovery of human platelets stored for five days in a non-plasma medium. Blood 1986;67:672-5.
21. Rock G, Swenson SD, Adams GA. Platelet storage in a plasma-free medium. Transfusion 1985;25:551-6.
22. Rock G, White J, Labow R. Storage of platelets in balanced salt solutions: a simple platelet storage medium. Transfusion 1991;31:21-5.
23. Ringwald J, Zimmermann R, Eckstein R. The new generation of platelet additive solution for storage at 22°C: development and current experience. Transfus Med Rev 2006; 20:158-64.
24. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer TransfusionWorking Party of the International Society of Blood Transfusion. Transfusion 1998;38:31-40.
25. Kunicki TJ, Tuccelli M, Becker GA, Aster RH. A study of variables affecting the quality of platelets stored at "room temperature." Transfusion 1975;15:414-21.
26. VandenBroeke T, Dumont LJ, Hunter S, Nixon J, Murphy S, Roger J, Herschel L, AuBuchon JP, Gulliksson H, Dengler T, Hornsey V, Prowse C; for the Biomedical Excellence for Safer TransfusionWorking Party of the International Society of Blood Transfusion. Platelet storage solution effects on the accuracy of laboratory tests for platelet function: a multi-laboratory study. Vox Sang 2004;86:183-8.
27. Lotter MG, Rabe WL, Van Zyl JM, Heyns AD, Wessels P, Kotze HF, Minnaar PC. A computer program in compiled BASIC for the IBM personal computer to calculate the mean platelet survival time with the multiple hit and weighted mean methods. Comput Biol Med 1988;18:305-15.
28. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames (IA): Iowa State University Press; 1967.
29. Rock G, Tittley P, Adams GA. Donor variables affecting survival of autologous platelets. Transfusion 1986;26:30-6.
30. Rock G, Sherring VA, Tittley P. Five-day storage of platelet concentrates. Transfusion 1984;24:147-52.
31. AuBuchon JP, Herschel L, Roger J, Murphy S. Prelimnary validation of a new standard of efficacy for stored platelets. Transfusion 2004;44:36-41.
32. AuBuchon JP, Taylor H, Holme S, Nelson E. In vitro and in vivo evaluation of leukoreduced platelets stored for 7 days in CLX containers. Transfusion 2005;45:1356-61.
33. Cardigan R, Williamson LM. The quality of platelets after storage for 7 days. Transfus Med 2003;13:173-87.
34. Vassallo RR, Murphy S. A critical comparison of platelet preparation methods. Curr Opin Hematol 2006;13:323-30.
35. Gulliksson H. Additive solutions for the storage of platelets for transfusion. Transfus Med 2000;10:257-64.
36. Slichter SJ, Corson J, Jones MK, Christoffel T, Pellham E, Bailey SL, Bolgiano D. Extended storage of autologous apheresis platelets in plasma or Plasmalyte [Abstract #2108]. Blood 2009;114:831.
37. Niu X, Whisson ME, Guppy M. Types and sources of fuels for platelets in a medium containing minimal added fuels and a low carryover plasma. Br J Haematol 1997;97: 908-16.
38. Murphy S. The efficacy of synthetic media in the storage of human platelets for transfusion. Transfus Med Rev 1999;13: 153-63.
39. Rinder HM, Smith BR. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion 2003;43:2-6.
40. Murphy S. Utility of in vitro tests in predicting the in vivo viability of stored platelets [Letter]. Transfusion 2004;44: 618-9.
41. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer C, Woodson R. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
42. Slichter SJ, Corson J, Jones MK, Pellham E, Christoffel T, Bailey S, Bolgiano D. Post-transfusion viability of 7-day stored platelet concentrates prepared after an overnight hold of whole blood at 22°C [abstract]. Blood 2008;112(11, Part 1):112.